Roche Advances in Spectrometry with the Launch of Cobas Mass Spec

Roche launches innovative device for spectrometry. The Swiss pharmaceutical multinational has presented cobas Mass Spec, a device capable of performing mass spectrometry.

Specifically, Roche has received CE Mark approval for the device solution in question, which uses innovation to bring automated, integrated and standardized clinical mass spectrometry testing to laboratories .

With this launch, Roche will offer more than sixty analytical tests for steroid hormones, vitamin D metabolites, immunosuppressive drugs, drug screening, as well as therapeutic drug monitoring.

“This solution will make mass spectrometry standardized and more widely available to improve patient care worldwide,” said Matt Sause, CEO of Roche Diagnostics, in a statement.

Roche plans to use this new technology in patients receiving hormonal therapy such as those with breast cancer, for example

One of the cases where Roche’s new technology would add value is in the case of patients with breast cancer who receive hormonal therapy , since mass spectrometry can help professionals detect subtle changes in the therapeutic response earlier.

In addition, cobas Mass Spec can contribute to the effective and responsible use of antibiotics and to the continuous monitoring of disease progression and treatments. The high specificity of tests performed with this technology provides greater levels of clarity to physicians and more timely decision-making for patient health.

Roche’s new technology enables automation with a workflow that is much more environmentally sustainable than currently used methods.

cobas Mass Spec is part of Roche’s strategic plan, which integrates clinical chemistry and immunochemistry testing, as well as laboratory automation and information technologies.

Roche recently acquired the American biopharmaceutical company Poseida Therapeutics for 1.5 billion dollars. The Swiss group closed the first nine months of the year with revenues of 48.118 billion euros, 2.1% more than in the same period of the previous year.

__

(Featured image by National Cancer Institute via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us